KRYS
Krystal Biotech, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$332.29Close
$9.7BMarket cap
$189.08 – $378.1552-week range
Nov 2, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 83 · stronger than 83% of stocks over 12 months
- Earnings growing EPS +39% year on year
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 6.7%
price change
1mo
down 0.1%
price change
12-month return
up 76%
market up 11% ·
its own up 69%
F-score
—
— Not assessed
Altman Z
52.49
Low risk
P/E
47.4×
price / earnings
PEG
0.37
P/E / EPS growth
P/B
8.0×
price / book
Earnings yield
up 1.8%
EBIT / enterprise value
Cheaper than
30%
of the market · expensive
Revenue growth
up 34%
year on year
EPS growth
up 39%
latest quarter · -15 pts
Sales growth
up 24%
latest quarter · -8 pts
ROE
up 19%
return on equity
Free cash margin
up 49%
$188.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-3.1×
net cash
Interest cover
—EBIT / interest
Trade setup
ATR%
3.0%
$10.07 a day · 2×ATR $312.16
RS
83 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.2×
vs 50-day average
Up/down volume
0.76
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 3, 2026
Results reaction
Aug 3, 2026-8% vs market2 sessions after results
Financials
- Net 53%
- Free cash 49%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Operating income | -$33.0M | -$68.3M | -$145.2M | -$109.6M | $65.7M | $161.3M |
| Net income | -$32.2M | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| Net margin | — | — | — | 22% | 31% | 53% |
| Earnings per share | -$1.71 | -$3.13 | -$5.49 | $0.39 | $3.00 | $6.84 |
| Free cash flow | -$40.9M | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
| Free cash margin | — | — | — | -198% | 41% | 49% |
| Cash | $268.3M | $341.2M | $161.9M | $358.3M | $344.9M | $496.3M |
| Shareholders' equity | $292.1M | $593.6M | $522.2M | $778.6M | $946.4M | $1.2B |
| Shares outstanding | 19.71m | 25.21m | 25.76m | 28.24m | 28.79m | 29.19m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 17, 2026 | Annual ↗ | Dec 31, 2025 | 48d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 19, 2025 | Annual ↗ | Dec 31, 2024 | 50d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 15, 2026 | Regulation FD ↗ |
| Aug 3, 2026 | Results ↗ |
| Jul 21, 2026 | Other events ↗ |
| May 20, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Exhibits only ↗ |
| Feb 17, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Jan 8, 2026 | Regulation FD ↗ |
| Dec 23, 2025 | Director or officer change ↗ |
| Nov 3, 2025 | Results ↗ |
| Oct 22, 2025 | Other events ↗ |
| Aug 4, 2025 | Results ↗ |